In a recent study posted to the medRxiv* preprint server, researchers investigated the impact of the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) exposure in utero on the neurodevelopment of children.

Study: Sex-specific neurodevelopmental outcomes in offspring of mothers with SARS-CoV-2 in pregnancy: an electronic health records cohort. Image Credit: adike/Shutterstock

Studies have reported that the neuropsychological effects of SARS-CoV-2 exposure among children and adults are of concern, since even the lack of direct central nervous system exposure to SARS-CoV-2 could cause persistent effects on the brain, which may be sex-specific. The present study’s authors previously documented preliminary proof of a positive association between maternal SARS-CoV-2-positive status and delayed speech and motor development among infants.

About the study

In the present retrospective cohort study, researchers extended their previous analysis by investigating sex-based differences in neurodevelopmental disorder diagnosis rates among children exposed to SARS-CoV-2 in utero compared to those lacking such exposure in a much larger cohort.

The study cohort comprised 18,323 infants delivered between March 1, 2018, and May 31, 2021, at one of the eight Eastern Massachusetts hospitals, including six community-based hospitals, two centers for tertiary care, and their affiliated outpatient connections. Data were obtained from the Massachusetts general hospital, Newton-Wellesley Hospital, Brigham and Women’s Hospital, Martha’s Vineyard Hospital, North Shore medical center, Cooley Dickinson Hospital, Wentworth Douglass Hospital, and Nantucket Cottage Hospital.

The study exposure was polymerase chain reaction (PCR)-confirmed maternal coronavirus disease 2019 (COVID-19) during pregnancy. The prime study outcome and measures were electronic health record (EHR) reporting of the international classification of diseases and tenth revision (ICD-10) diagnostic codes corresponding to neurodevelopmental disorders.

In addition to infants with SARS-CoV-2 exposure in utero (COVID-19 cohort), a pre-pandemic cohort comprised infants born and assessed between 1 January and 31 December 2018. Further, for sensitivity analysis, another group of infants born before COVID-19, and assessed during COVID-19 at least partially, including infants born between 1 January and 31 December 2019, was included for evaluating ascertainment bias.

The newborns were linked to their mothers based on the medical record numbers, the sex of the newborns, and the time and date of birth. The mothers’ medical records were characterized based on ICD-10 codes, medications, problem lists, and laboratory-based studies conducted between the dates of the most recent menstruation and discharge for delivery admission. Logistic regression modeling was used to assess the association between maternal SARS-CoV-2 status and neurodevelopmental outcomes in children within a year of birth. 

Data were adjusted for ethnicity, race, the status of insurance (public or private), type of hospital (community-based versus academic center-based), mothers’ age, and preterm delivery status, and the odds ratios (OR) were calculated. The robustness of regression analysis findings was assessed by applying an exact matching approach in which every SARS-CoV-2-exposed infant was matched with one or more unexposed infants for features used in the regression analysis.

Results

Out of the pandemic cohort, five percent (n=877) of infants were born to mothers with SARS-CoV-2-positive status during pregnancy. Among the sample population, 10% (n=1,806), nine percent (n=1,634), 69% (n=12,694), and nine percent (n=1,711) were Asian, Black, White, and of another race, respectively, of which, 14% (n=2,614) were Hispanic. The average maternal age was 33 years. Three percent (n=26) of SARS-CoV-2-exposed infants and two percent (n=316) of the unexposed ones were diagnosed with neurodevelopmental disorders during the initial year post-delivery.

Three SARS-CoV-2-unexposed children and no SARS-CoV-2-exposed children died before the follow-up period. Males born to PCR-confirmed SARS-CoV-2-positive mothers showed a greater likelihood of being diagnosed with neurodevelopmental diseases in the initial year of life, even after the preterm delivery status was considered. SARS-CoV-2-positive maternal status was associated with a significantly greater neurodevelopmental disease risk among male infants (OR 2.0).

However, the association was numerically similar but non-significant in the pooled analysis (OR 1.5). Matching male, female, and pooled (both sexes) SARS-CoV-2-exposed and unexposed newborns yielded OR values of 1.9, 1.2, and 1.6, respectively. Consistency in effect direction was observed across the regression model and matched analyses after the sensitivity analyses. At the 18-month follow-up of 551 SARS-CoV-2-exposed and 13,435 unexposed children, similar results were obtained for neurodevelopmental outcomes in male newborns (OR 1.4) but not among females.

The pooled analysis findings showed a numeric but non-significant elevation in neurodevelopmental disorder diagnosis (OR 1.3) among newborns born to SARS-CoV-2-positive mothers. Similar results were obtained after eliminating preterm births. Compared to the 2018 pre-pandemic cohort, a modest but non-significant elevation in neurodevelopmental outcomes was noted among male and female infants with OR values of 1.1 and 1.3, respectively, and pooling both genders yielded an OR value of 1.2. The corresponding OR values for the 2019 cohort for male, female, and pooled (both sexes) infants were 1.2, 1.2, and 1.2, respectively.

Overall, the study findings showed that SARS-CoV-2 exposure in utero was associated with an increased risk of adverse neurodevelopmental outcomes among male newborns in the initial year of life. However, further research with larger sample sizes and longer follow-up period are required to validate the study findings.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:



Source link

By Josh

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.